FINSUM + Magnifi: Goldman Picks These Three Medical Stocks for a 100% Rally

Magnifi in Action: Discover "Growth Funds"

Click on any fund in the chart below to dig deeper.

June 25, 2021

The recent market turmoil has made some investors skittish over what to do in the stock market. But strategist David Kostin at Goldman Sachs sees global reopening, elevated consumer savings, and corporate operating leverage creating an environment where equity is still appealing over bonds. Goldman analysts see Rain Therapeutics as a strong growth buy, with a number of cancer treatments in the pipeline for long-term prospects. Relmada Therapeutics is a pharmaceutical firm focusing on the central nervous system, and that the US weening off the opioids and pipeline drugs makes it a strong buy. Finally, Agiliti is a high-potential medical equipment company with statements that look promising.

(New York)

FINSUM + Magnifi: Value has been the predominant push for most as of late, but for those looking at growth stocks these pharmaceuticals could be promising. 

Other news today: Dodge China’s Most Fearsome Regulators With These Funds and The Next Big Growth Trend in ESG
 


New call-to-action

Magnifi is changing the way we shop for investments, with the world’s first semantic search engine for finance that helps users discover, compare and buy investment products such as ETFs, mutual funds and stocks. As of June 2021, 380,000+ users with $534+ Billion in Assets Under Influence, have used Magnifi over 3,800,000 times. Try it for yourself today.

 

This blog is sponsored by Magnifi. The information and data are as of the publish date unless otherwise noted and subject to change. This material is provided for informational purposes only and should not be construed as individualized investment advice or an offer or solicitation to buy or sell securities tailored to your needs. This information covers investment and market activity, industry or sector trends, or other broad-based economic or market conditions and should not be construed as investment research or advice. Investors are urged to consult with their financial advisors before buying or selling any securities. Although certain information has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness. Past performance is no guarantee of future results. This content may not be reproduced or distributed to any person in whole or in part without the prior written consent of Magnifi. [As a technology company, Magnifi provides access to tools and will be compensated for providing such access. Magnifi does not provide brokerage or custody services.]